Mount Sinai School of Medicine has just entered into "a territory limited license agreement with Avimex Animal Health" to produce a new biological that combines an H5 flu vaccine combined with portion of another important disease virus for commercial poultry, Newcastle Disease.
The privately owned world-leader in the avian influenza H5 emulsified vaccine market will use Mount Sinai's patented live recombinant Newcastle disease technology that contains an insertion of the H5 gene, for use in Brazil, India, Japan, Mexico, and Taiwan.
Inventors, Peter Palese, PhD, Chairman and Professor,…
Advertisment
